Is Pralsetinib a targeted drug?

Pralsetinib (Pralsetinib) is a targeted drug, a third-generation targeted drug, also known as a RET inhibitor. It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which are mainly used to treat certain tumors with RET gene mutations, such as thyroid cancer and non-small cell lung cancer. This drug blocks the growth and spread of tumors by inhibiting the abnormally active RET protein. Platinib studies have demonstrated significant therapeutic efficacy and high tolerability in specific tumor types. Platinib is provided in the form of oral capsules. The recommended dose is 400 mg once daily on an empty stomach. No food should be eaten for at least 2 hours before and for at least 1 hour after taking Platinib.